A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
← catalyst calendarNCT06487156 · readout in 1,514 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
404actual
Sites
1
Country
Italy
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-11 | actual | When the study began enrolling |
| Primary completion | 2030-10-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-10-11 | estimated | The whole study's end, after follow-up |
| First posted | 2024-07-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-small Cell Lung Cancer (NSCLC)
Intervention
- Drug: Nivolumab + ipilimumab
Primary outcome
what the primary-completion date above is the date OFOverall survival (OS)
measured Up to 5 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed